Women More Susceptible to Early-Onset Mycosis Fungoides

After examining data from over 1000 patients over an 18 year span, researchers from Houston’s University of Texas M.D. Anderson Cancer Center concluded that women (whites, blacks and Hispanics) are more likely than men to have the most common type of cutaneous T-cell lymphoma prior to turning 40 years old: early-onset mycosis fungoides.



Also known as Alibert-Bazin syndrome, mycosis fungoides is a highly treatable type of non-Hodgkin lymphoma (NHL) that affects the skin.



The research was published in February’s Journal of the American Academy of Dermatology



The most alarming observation was how much more further the mycosis fungoides had progressed in black women compared to white or Hispanic women—a phenomenon for which the researchers could not provide a clear answer, writing “Our clinical experience suggests that young women with aggressive mycosis fungoides … should be considered for allogenic transplantation, and that finding a match for African American patients may pose a significant challenge.”



Regardless, they concluded that making any sort of generalizations about prevalence and prognosis of mycosis fungoides is a sketchy proposition at best, and is likely most useful in “risk stratification and therapy choice."

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap